Cardio-Oncology Practice Manual: A Companion to Braunwald’s Heart Disease

Cardio-Oncology Practice Manual: A Companion to Braunwald’s Heart Disease

1st Edition - January 11, 2022

Write a review

  • Editor: Joerg Herrmann
  • eBook ISBN: 9780323681360
  • Paperback ISBN: 9780323681353

Purchase options

Institutional Subscription

Free Global Shipping
No minimum order

Description

Today’s patients have unique cardiologic needs before, during, and after cancer treatment. Chemotherapies, radiation therapy, and targeted therapies can produce acute side effects or lasting adverse consequences on the heart and circulatory system, making the field of cardio-oncology increasingly important in effective patient care. Cardio-Oncology Practice Manual is a comprehensive, portable guide that provides practical approaches to assessment and management of cardiovascular diseases due to the effects of cardiotoxic agents and treatments. Part of the Braunwald family of renowned cardiology references, it clearly presents clinically relevant aspects of this growing field in one quick, practical reference for a wide range of cardio-oncology providers.

Table of Contents

  • Cover image
  • Title page
  • Table of Contents
  • Copyright
  • Dedication
  • Contributors
  • Acknowledgments
  • Foreword
  • Preface
  • Braunwald’s heart disease family of books
  •     List of Tables
  •     List of Illustrations
  • 1.  The cardio-oncology clinic: Goals, scope, and focus of practice
  •     Milestone #1: Goals and vision
  •     Milestone #2: Institutional support and organization
  •     Milestone #3: Implementation and operation
  •     Approach to the patient with cancer at risk of or with evident cardiovascular disease
  •     References
  • Part I. Cardiovascular Disease Management Before Cancer Treatment
  • Section A. General Considerations
  • 2.  Key points of cardio-oncology evaluation before cancer therapy
  • 3.  Cardiovascular risks of chemotherapy
  •     Traditional chemotherapy
  •     Targeted therapies
  •     References
  • 4.  Radiation therapy cardiovascular risks
  •     Radiation dose and technique
  •     Age at time of exposure
  •     Time interval after radiation therapy
  •     Anthracycline exposure
  •     Comorbid conditions
  •     Risks during or early after RT
  •     Cardiac biomarkers
  •     Strain imaging
  •     Future avenues
  •     References
  • 5.  Bone marrow transplantation risks
  •     Hematopoietic stem cell transplantation and conditioning regimens
  •     Pretransplant screening
  •     Peritransplant management
  •     Early posttransplant management (until day 100)
  •     Late posttransplant management (after day 100)
  •     References
  • 6.  Surgical risks
  •     Preoperative cardiovascular risk assessment
  •     Risk of myocardial infarction (MI)
  •     Risk of heart failure decompensation
  •     Risk of cerebrovascular events (CVE)
  •     Risk of venous thromboembolic events (VTE)
  •     Unique risk assessment in specific cancers
  •     Breast cancer
  •     Lung cancer
  •     Colorectal cancer
  •     Cardiac tumors
  •     Malignant pericardial effusions
  •     Unique considerations for cancer survivors undergoing cardiac surgery
  •     Cardiopulmonary bypass (CPB)
  •     Valve surgery
  •     Advanced heart failure therapies in cancer survivors
  •     Risks in patients with prior mediastinal radiation
  •     Conclusion
  •     References
  • Section B. The A-to-Z Before Therapy
  • 7.  Prevention of heart failure and cardiomyopathy in patients with cancer
  •     Establishing a patient’s cardiovascular risk
  •     Treatment-related risk
  •     Primary and secondary preventative strategies
  •     Screening and monitoring
  •     Inflammatory markers, such as high-sensitivity C-reactive protein (HS-CRP), may be useful in guiding clinical decision making when myocarditis is suspected.
  •     Referral to cardio-oncology
  •     References
  • 8.  Vascular disease prevention: Before cancer therapy
  •     Vascular risks and identifying the patient at high risk
  •     Prevention
  •     References
  • 9.  Thromboembolic disease prevention before cancer therapy
  •     Risk assessment
  •     Overview of prophylaxis guidelines
  •     Evolving role of direct oral anticoagulants and the changing landscape
  •     References
  • 10.  Arrhythmia prevention and device management: Before cancer therapy
  •     Atrial fibrillation and other atrial arrhythmias
  •     QT interval assessment
  •     Cardiac implantable electronic device evaluation
  •     References
  • 11.  Hypertension and renal disease prevention before cancer therapy
  •     Risk stratification and screening for hypertension and renal dysfunction
  •     Correcting modifiable risk factors
  •     Diagnosis and monitoring of hypertension before treatment
  •     Renal disease in patients with cancer
  •     Estimation of renal function in patients with cancer
  •     Renal dysfunction and implications for management
  •     Cancer-associated renal disease
  •     Cancer therapy-induced renal disease
  •     Acknowledgments
  •     References
  • 12.  Prevention and management of pulmonary conditions in patients with cancer before therapy
  •     General recommendations
  •     Surgery-related recommendations
  •     Chemotherapy-related recommendations
  •     References
  • 13.  Cardiopulmonary exercise for management of cardiovascular toxicity
  •     Exercise to modulate cardiovascular toxicity: Overview of the evidence
  •     Exercise across the cancer continuum
  •     Implementation of exercise in patients with a history of cancer
  •     Identification of patients with high cardiovascular risk
  •     Physical activity
  •     Summary
  •     References
  • Part II. Cardiovascular Disease Management During Cancer Treatment
  • Section C. The A-to-Z Through Therapy
  • 14.  Key points of cardio-oncology evaluation during cancer therapy
  • 15.  Diagnosis and management of cardiomyopathy and heart failure during cancer treatment
  •     Stress-induced (Takotsubo) cardiomyopathy in patients with cancer
  •     Immune checkpoint inhibitors and cardiac immune-related adverse events
  •     References
  • 16.  Structural heart disease management during cancer treatment
  •     Pericardial disease
  •     Valve disease
  •     References
  • 17.  Vascular disease during cancer therapy
  •     Presentations
  •     Diagnosis
  •     Treatment
  •     Implications for cancer therapy and secondary prevention
  •     References
  • 18.  Thromboembolic disease treatment during cancer therapy
  •     Treatment trials
  •     Summary
  •     References
  • 19.  Arrhythmia and device assessment during cancer treatments
  •     Atrial fibrillation and other supraventricular arrhythmias
  •     Anthracyclines
  •     Alkylating agents and stem cell transplantation
  •     Tyrosine kinase inhibitors
  •     Proteasome inhibitors
  •     Immunotherapy
  •     Management of atrial fibrillation and atrial arrhythmias
  •     QT prolongation and ventricular arrhythmias
  •     Anthracyclines
  •     Arsenic trioxide
  •     Fluoropyrimidines
  •     Tyrosine kinase inhibitors
  •     Cyclin-dependent kinase 4/6 inhibitors
  •     Bradyarrhythmias and autonomic dysfunction
  •     Cardiac implantable electronic devices
  •     References
  • 20.  Hypertension and renal disease during anti-cancer therapies
  •     Hypertension risk during anti-cancer therapies
  •     Acute kidney injury
  •     Nephrotoxicity of cancer drugs
  •     Acknowledgments
  •     References
  • 21.  Pulmonary disease during cancer therapy
  •     Overview of pulmonary complications of cancer therapy and their evaluation
  •     Pulmonary toxicity associated with antineoplastic agents
  •     Radiation-induced lung injury
  •     References
  • 22.  Cardiovascular testing in patient with cancer
  •     Echocardiography
  •     Cardiac magnetic resonance (CMR) imaging
  •     Nuclear imaging
  •     Cardiac computer tomography (CT)
  •     Conclusion
  •     References
  • Part III. Cardiovascular Disease Management After Cancer Treatment
  • Section D. General Considerations
  • 23.  Key points of cardio-oncology evaluation after cancer therapy
  • 24.  Cancer survivorship and comorbidity disease risk after cancer treatment
  •     Populations at risk
  •     Management of cardiovascular (CV) risk factors
  •     Special issues in cancer survivorship
  •     Predictors of late effects
  •     Surveillance recommendations: What tests and how often?
  •     References
  • 25.  Long-term complications of chemotherapy
  •     Anthracyclines
  •     Targeted HER2 therapy
  •     VEGF signaling pathway inhibitors
  •     Other tyrosine kinase inhibitors
  •     Platinum- based chemotherapy
  •     Antiestrogen therapy
  •     Androgen deprivation therapy
  •     Conclusions
  •     References
  • 26.  Long-term consequences of radiation therapy
  •     Coronary artery disease
  •     Valvular heart disease
  •     Cardiomyopathy
  •     Pericardial disease
  •     Peripheral artery disease
  •     Arrhythmias and autonomic dysfunction
  •     Prevention and screening for RIHD
  •     Preventive drug therapies
  •     Future avenues
  •     References
  • Section E. The A-to-Z After Therapy
  • 27.  Prevention and management of cardiomyopathy and heart failure in cancer survivors
  •     Advanced HF therapy in cancer survivors
  •     Cardio-oncology rehabilitation
  •     References
  • 28.  Structural heart disease prevention and management in cancer survivors
  •     Pericardial disease
  •     Valve disease
  •     References
  • 29.  Vascular disease prevention and management after cancer therapy
  •     General considerations
  •     Follow-up screening
  •     Treatment
  •     Prevention
  •     References
  • 30.  Prevention of VTE after initial presentation and cancer treatment
  •     Introduction
  •     Patient and tumor-specific risk of VTE
  •     Prevention of recurrent VTE and VTE in cancer survivor
  •     Summary
  •     References
  • 31.  Arrhythmia prevention and management in cancer survivors
  •     Atrial and ventricular arrhythmias in cancer survivors
  •     Autonomic dysfunction and bradyarrhythmia
  •     Cardiac implantable electronic devices in cancer survivors
  •     References
  • 32.  Hypertension and renal failure prevention and management after cancer therapy
  •     Hypertension
  •     Renal disease
  •     Chronic kidney disease after hematopoietic stem cell therapy
  •     Calcineurin inhibitor toxicity
  •     Management of HSCT-Related CKD
  •     Acknowledgments
  •     References
  • 33.  Monitoring for and management of delayed complications after cancer therapy
  •     Introduction
  •     Parenchymal disease
  •     Airway disease
  •     Vascular disease
  •     Pleural disease
  •     Neuromuscular disease
  •     Secondary intrathoracic malignancy
  •     Long-term monitoring and prevention of complications
  •     References
  • 34.  Cardio-oncology rehabilitation for patients with cancer and survivors
  •     Interrelationship of cancer and cardiovascular diseases
  •     Exercise capacity (cardiorespiratory fitness) is reduced in patients with cancer and improves with exercise training
  •     Exercise training improves prognosis for patients with cancer and exercise guidelines have been published but are not widely followed
  •     Cardio-oncology rehabilitation: Partnering with existing cardiac rehabilitation programs to improve symptoms, cardiorespiratory fitness, and cardiovascular health in patients with cancer
  •     Summary
  •     References
  • Section F. Cardiovascular Disease Management in Specific Malignant Diseases
  • 35.  Breast cancer
  •     Incidence
  •     Risk factors
  •     Prognosis
  •     Treatment overview
  •     Cardiovascular risk
  •     References
  • 36.  Gynecologic malignancies
  •     Endometrial cancer
  •     Ovarian cancer
  •     Cervical cancer
  •     Cardiovascular side effects of systemic cancer treatments in gynecologic malignancies
  •     References
  • 37.  Prostate and testicular cancer
  •     Testicular cancer
  •     Prostate cancer
  •     Survivorship
  •     Conclusions
  •     References
  • 38.  Renal and urinary bladder cancer
  •     Bladder cancer
  •     Renal cell carcinoma
  •     References
  • 39.  Lung cancer
  •     Epidemiology
  •     Risk factors and screening
  •     Diagnosis and staging
  •     Treatment
  •     Cardiovascular and pulmonary toxicity
  •     References
  • 40.  Colorectal cancer
  •     Incidence and risk factors
  •     Presentation
  •     Initial workup
  •     Imaging staging
  •     Prognosis
  •     Treatment overview
  •     Early stage disease (stages I–III)
  •     Principle of resection of distant metastases
  •     Molecular testing
  •     Palliative therapy
  •     Rectal cancer
  •     Cardiovascular risks
  •     References
  • 41.  Esophageal and gastric cancer
  •     Esophageal cancer
  •     Gastric cancer
  •     References
  • 42.  Hepatobiliary carcinomas
  •     Hepatocellular carcinoma
  •     Biliary tract cancers
  •     References
  • 43.  Pancreatic cancer
  •     Incidence
  •     Risk factors
  •     Prognosis
  •     Treatment overview
  •     Cardiovascular risk
  •     References
  • 44.  Cutaneous melanoma
  •     Cutaneous melanoma
  •     Cardiovascular side effects of systemic cancer treatments in metastatic melanoma
  •     Summary
  •     References
  • 45.  Head and neck cancers
  •     Incidence
  •     Risk factors
  •     Diagnosis and staging
  •     Treatment overview
  •     Cardiovascular risk
  •     Cardiovascular side effects of head and neck cancer therapy
  •     References
  • 46.  Thyroid cancer
  •     Incidence
  •     Risk factors
  •     Prognosis
  •     Staging of thyroid cancer
  •     Treatment
  •     Surgery
  •     Cardiovascular risks
  •     TSH suppression therapy (iatrogenic subclinical hyperthyroidism)
  •     Chemotherapy
  •     Tyrosine kinase inhibitor and immunotherapy
  •     Immunotherapy
  •     References
  • 47.  Glioblastoma
  •     Incidence
  •     Risk factors
  •     Background
  •     Prognosis
  •     Treatment overview
  •     Cardiovascular risk
  •     References
  • 48.  Introduction to the management of soft tissue sarcomas
  •     Introduction
  •     Epidemiology
  •     Risk factors and screening
  •     Diagnosis and staging
  •     Prognosis
  •     Treatment
  •     Basic principles of treating advanced/metastatic STS
  •     Treatment beyond failure of first-line chemotherapy
  •     Emerging nonchemotherapeutic treatment options in the management of STS
  •     Cardiovascular risk
  •     Summary
  •     References
  • 49.  Acute and chronic leukemias
  •     Introduction
  •     Prognosis
  •     Treatment strategies for acute myeloid and lymphoid malignancies
  •     Treatment strategies for chronic myeloid and lymphoid malignancies
  •     Conclusion
  •     References
  • 50.  Lymphomas
  •     Introduction
  •     Diffuse large B-cell non-hodgkin lymphoma and other aggressive lymphomas
  •     Follicular lymphoma
  •     Marginal zone lymphoma
  •     Treatment overview
  •     Lymphoplasmactytic lymphoma/Waldenström’s macroglobulinemia
  •     Hodgkin lymphoma
  •     Conclusion
  •     References
  • 51.  Multiple myeloma and cardiac amyloidosis
  •     Introduction
  •     Diagnosis and differential diagnosis
  •     Prognosis
  •     Treatment and side effects
  •     Toxicity of therapy
  •     Conclusions
  •     References
  • 52.  Carcinoid tumors and carcinoid heart disease
  •     Introduction
  •     Carcinoid heart disease
  •     Tumor therapy
  •     Periprocedural considerations
  •     Conclusions
  •     References
  • 53.  Neoplasms and the heart
  •     Introduction
  •     Malignant neoplasms
  •     Primary benign cardiac neoplasms
  •     Conclusions
  •     References
  • Part IV. Cancer Drugs
  • 54.  Cancer therapeutic drug guide
  •     Antitumor antibiotics and topoisomerase inhibitors including anthracyclines
  •     Alkylating agents
  •     Antimetabolites
  •     Mitosis inhibitors
  •     Monoclonal antibodies
  •     Multi-tyrosine kinase inhibitors
  •     Immune checkpoint inhibitors
  •     CAR T-cell therapy
  •     Proteasome inhibitors
  •     mTOR/phosphatidylinositol-3-kinase (PI3K) inhibitors
  •     Biological response modifiers and differentiation agents
  •     Differentiation agents and differentiation syndrome
  •     Biological response modifiers
  •     Conclusions
  •     Miscellaneous
  •     References
  • Index

Product details

  • No. of pages: 544
  • Language: English
  • Copyright: © Elsevier 2022
  • Published: January 11, 2022
  • Imprint: Elsevier
  • eBook ISBN: 9780323681360
  • Paperback ISBN: 9780323681353

About the Editor

Joerg Herrmann

Affiliations and Expertise

Professor of Medicine, Department of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota

Ratings and Reviews

Write a review

There are currently no reviews for "Cardio-Oncology Practice Manual: A Companion to Braunwald’s Heart Disease"